- Japan
- /
- Medical Equipment
- /
- TSE:7779
CYBERDYNE Inc.'s (TSE:7779) Earnings Haven't Escaped The Attention Of Investors
CYBERDYNE Inc.'s (TSE:7779) price-to-sales (or "P/S") ratio of 10.8x may look like a poor investment opportunity when you consider close to half the companies in the Medical Equipment industry in Japan have P/S ratios below 1.9x. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so lofty.
See our latest analysis for CYBERDYNE
What Does CYBERDYNE's P/S Mean For Shareholders?
CYBERDYNE could be doing better as its revenue has been going backwards lately while most other companies have been seeing positive revenue growth. One possibility is that the P/S ratio is high because investors think this poor revenue performance will turn the corner. If not, then existing shareholders may be extremely nervous about the viability of the share price.
Want the full picture on analyst estimates for the company? Then our free report on CYBERDYNE will help you uncover what's on the horizon.How Is CYBERDYNE's Revenue Growth Trending?
CYBERDYNE's P/S ratio would be typical for a company that's expected to deliver very strong growth, and importantly, perform much better than the industry.
Taking a look back first, the company's revenue growth last year wasn't something to get excited about as it posted a disappointing decline of 4.3%. However, a few very strong years before that means that it was still able to grow revenue by an impressive 47% in total over the last three years. Although it's been a bumpy ride, it's still fair to say the revenue growth recently has been more than adequate for the company.
Shifting to the future, estimates from the three analysts covering the company suggest revenue should grow by 11% per year over the next three years. Meanwhile, the rest of the industry is forecast to only expand by 6.3% each year, which is noticeably less attractive.
With this information, we can see why CYBERDYNE is trading at such a high P/S compared to the industry. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.
What Does CYBERDYNE's P/S Mean For Investors?
Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.
Our look into CYBERDYNE shows that its P/S ratio remains high on the merit of its strong future revenues. It appears that shareholders are confident in the company's future revenues, which is propping up the P/S. Unless these conditions change, they will continue to provide strong support to the share price.
Don't forget that there may be other risks. For instance, we've identified 1 warning sign for CYBERDYNE that you should be aware of.
Of course, profitable companies with a history of great earnings growth are generally safer bets. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
β’ Dividend Powerhouses (3%+ Yield)
β’ Undervalued Small Caps with Insider Buying
β’ High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:7779
CYBERDYNE
Researches, develops, produces, sell, leases, and maintains robotic equipment and systems for medical and welfare in Japan, the United States, Europe, the Middle East, Africa, and the Asia Pacific countries.
Excellent balance sheet with reasonable growth potential.
Similar Companies
Market Insights
Weekly Picks

The "Sleeping Giant" Stumbles, Then Wakes Up
Swiped Left by Wall Street: The BMBL Rebound Trade

Duolingo (DUOL): Why A 20% Drop Might Be The Entry Point We've Been Waiting For
Recently Updated Narratives

The "Molecular Pencil": Why Beam's Technology is Built to Win
Intuit Stock: When Financial Software Becomes the Operating System for Small Business
Metaβs Bold Bet on AI Pays Off
Popular Narratives

The "Sleeping Giant" Stumbles, Then Wakes Up

